Monday, November 07, 2005


Although this company has 2 approved drugs on the market (ever hear of Velcade?), and its been trying to cut unneccessarry costs in order to become profitable, it is actually not going to effect its short term gains, but its potential pipeline drugs may get the axe.

While Millenium still has a pipeline with strong enough to consider it a speculative play, this company is beginning to focus more on oncology, but their potential to turn a profit may be realized, a rarity in the biotech's it seems.

As a note I received some shares of Millenium which were purchased at $9.15 as a form of debt repayment, I plan on holding onto this stock up to my price target of $10.50.

I am not responsible for your trade decisions made or not made because of my opinion shared here. You should always do your own research before buying/selling a stock.


At 5:12 PM, Blogger Salbert said...

A little boptech company I know of is Naabi Biopharma (NASDAQ: NABI). When a possible blockbuster drug they had did not get approved, their stock went from $15 to $3. That is why I don't like small biotech.

At 5:42 PM, Blogger Investing Monkey said...

thats the one thing that made MLNM slightly more appealing is that its not a 1 item live or die situation, stilll I didn't buy the stock and thought it was slightly cheap at the price it was bought.

But if I had to go with a 1 trick pony it'd pry be Avanair pharma (AVN) which I actually reccomended to by a former CEO in the pharma industry which I'll pry post a buy on at below $3 a share.


Post a Comment

<< Home